Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Propofol on Remifentanil-induced Postoperative Hyperalgesia in Patients Undergoing Thyroid Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2010 by Gangnam Severance Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Gangnam Severance Hospital
ClinicalTrials.gov Identifier:
NCT01189721
First received: August 25, 2010
Last updated: August 26, 2010
Last verified: August 2010
  Purpose

The investigators hypothesize that propofol infusion during surgery can affect the remifentanil hyperalgesia compared to sevoflurane inhalation.The outcome will be measured by a verbal numerical rating score (VNRS) and mechanical punctuating pain by electronic von frey filament.


Condition Intervention Phase
Hyperalgesia
Drug: propofol, sevoflurane
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Propofol on Remifentanil-induced Postoperative Hyperalgesia in Patients Undergoing Thyroid Surgery

Resource links provided by NLM:


Further study details as provided by Gangnam Severance Hospital:

Primary Outcome Measures:
  • Tactile pain thresholds adjacent to the surgical wound assessed by von Frey hair before the induction and at postoperative 24 & 48 hrs [ Time Frame: postoperative 48 hrs ] [ Designated as safety issue: No ]

Estimated Enrollment: 84
Study Start Date: August 2010
Estimated Study Completion Date: July 2011
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: sevoflurane
Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients who are in this group will be infused propofol intraoperatively.
Drug: propofol, sevoflurane

Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.

group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively.

Experimental: propofol
Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min. patients included this group will be inhaled sevoflurane intraoperatively.
Drug: propofol, sevoflurane

Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.

group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively.


  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients undergoing thyroidectomy
  • Age 20-65
  • American Society of Anesthesiologists physical status classification I or II

Exclusion Criteria:

  • History of chronic pain, Regular use of analgesic, antiepileptic or antidepressive drugs
  • History of drug & alcohol abuse
  • Psychiatric disorder
  • Use of opioids within 24hrs
  • Renal disease with decreased glomerular filtrate ratio
  • Neuromuscular disease, Severe cardiac disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01189721

Contacts
Contact: young ju won, MD. 082-2-2019-6805 moma2@naver.com
Contact: yuen hee shim, MD. 082-2-2019-6808 tren125@yuhs.ac

Locations
Korea, Republic of
Gang Nam Severance Hospital, Yonsei University, Anesthesia and Pain Medicine Department, Recruiting
Seoul, Korea, Republic of, 135-270
Contact: young ju won, MD    082-2-2019-6805    moma2@naver.com   
Sub-Investigator: young ju won, MD         
Sponsors and Collaborators
Gangnam Severance Hospital
Investigators
Study Chair: yuen hee shim, MD Gangnam severance hospital, Yonsei university, Department of Anesthesiology and Pain Medicine and Anesthesia and Pain Reseach Institute
  More Information

No publications provided

Responsible Party: Gang nam Severance Hospital, Anesthesia and Pain Research Institute, Anesthesia and Pain Research Institute
ClinicalTrials.gov Identifier: NCT01189721     History of Changes
Other Study ID Numbers: 3-2010-0102
Study First Received: August 25, 2010
Last Updated: August 26, 2010
Health Authority: Korea: Food and Drug Administration

Keywords provided by Gangnam Severance Hospital:
remifentanil
hyperalgesia

Additional relevant MeSH terms:
Hyperalgesia
Nervous System Diseases
Neurologic Manifestations
Sensation Disorders
Signs and Symptoms
Somatosensory Disorders
Propofol
Remifentanil
Sevoflurane
Analgesics
Analgesics, Opioid
Anesthetics
Anesthetics, General
Anesthetics, Inhalation
Anesthetics, Intravenous
Central Nervous System Agents
Central Nervous System Depressants
Hematologic Agents
Hypnotics and Sedatives
Narcotics
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014